Octreotide News and Research

RSS
Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Ga-68 DOTATATE PET/CT scans more effective than current imaging standard for detecting NETS

Ga-68 DOTATATE PET/CT scans more effective than current imaging standard for detecting NETS

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA approves Novartis Signifor injection for treatment of Cushing's disease